Title:
VBI COVID-19 Project
Agreement Value:
$55,976,000.00
Agreement Date:
Apr 13, 2020 - Mar 31, 2035
Description:
This project will support the development of Canada’s medical countermeasures (MCMs) in immediate response to COVID-19. Variation Biotechnologies Inc. (VBI) will advance the development of an enveloped Virus-Like-Particle (eVLP) vaccine candidate through clinical trials to provide protection against SARS-COV2 (COVID-19), MERS and SARS.
Organization:
Innovation, Science and Economic Development Canada
Expected Results:
This project will yield vaccine candidates for evaluation in a Phase III clinical trial, which will contribute to Canada’s vaccine portfolio against COVID-19. The project allows the development of Canadian intellectual property and for VBI to grow as a small-medium sized enterprise (SME) in Canada. This project anticipates the creation of 5 new full-time jobs and will maintain 25 full-time jobs within Canada.
Location:
Ottawa, Ontario, CA K1V1C1
Reference Number:
033-2020-2021-Q2-815774
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
867258410
Recipient Type:
For-profit organization
Additional Information:
The amendment has been completed to extend the agreement end date from December 31, 2031 to March 31, 2035.
Amendment Date
Mar 28, 2024
Recipient's Operating Name:
VBI Vaccines (Ontario Business Name Registration 260905344)
Recipient's Legal Name:
Variation Biotechnologies Inc.
Federal Riding Name:
Ottawa South
Federal Riding Number:
35077
Program:
SIF Stream2- Growth
Program Purpose:
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.